Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total value of $101,847.00. Following the transaction, the executive vice president directly owned 109,504 shares in the company, valued at $6,560,384.64. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $63.04, for a total value of $107,168.00.
• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $64.85, for a total value of $110,245.00.

DexCom Trading Up 2.9%

Shares of DXCM traded up $1.86 during mid-day trading on Tuesday, hitting $66.95. 11,299,467 shares of the company’s stock traded hands, compared to its average volume of 5,199,357. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a market capitalization of $25.83 billion, a P/E ratio of 28.61, a PEG ratio of 1.06 and a beta of 1.40. The business’s 50-day moving average price is $63.35 and its 200-day moving average price is $65.83.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm earned $0.32 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its holdings in DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC boosted its holdings in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth boosted its holdings in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after acquiring an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after acquiring an additional 258 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research analyst reports. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Truist Financial reaffirmed a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday. Mizuho set a $75.00 price target on DexCom in a research note on Friday, May 1st. Finally, Wells Fargo & Company reduced their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.